- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05845372
Association of Profylactic Use of Stress Ulcus Drugs och kliniska resultat hos patienter med akut främre cirkulationstrombektomi
Association of Profylactic Use of Stress Ulcus Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombeectomy: a Prospective, Multicenter, Observational Cohort Study
Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, and a previously proven incidence of stress ulcer bleeding after ischemic stroke. Stress ulcer bleeding after ischemic stroke has been shown to be closely associated with unfavorable outcomes, such as mortality. Current national and international guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for the prevention of stress ulcers, but rather should be considered in the context of the patient's risk factors for stress ulcers and discontinued after the patient initiates enteral nutrition. However, there is no evidence-based medical evidence to support the risk-benefit relationship of stress ulcer drug prophylaxis in patients with mechanical thrombectomy for acute anterior circulation large vessel occlusion.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, of which only 0.5%-1% require blood transfusion or result in hypotension. Stress ulcer bleeding after ischemic stroke has been shown to be associated with poor outcomes, such as mortality, and basilar artery occlusion and middle cerebral artery cerebral infarction are independent risk factors for stress ulcer bleeding after acute ischemic stroke. Guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for stress ulcer prevention.
However, stress ulcer prophylaxis is initiated in most patients admitted to the neurological intensive care unit after mechanical embolization of acute anterior circulation large vessel occlusion. With advances such as diagnosis and early initiation of enteral nutrition, the rate of stress ulcer bleeding in patients with mechanical embolization of acute anterior circulation large vessel occlusion is significantly reduced. The relationship between the risk and benefit of SUP in patients undergoing mechanical embolization for acute anterior circulation large vessel occlusion is not yet supported by evidence-based medical evidence. Therefore, the purpose of this study was to investigate the correlation between pharmacological stress ulcer prophylaxis and clinical outcomes in patients undergoing mechanical thrombectomy for acute anterior circulation large vessel occlusion.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Suyue Pan, M.D., Ph.D.
- Telefonnummer: 13556184981
- E-post: pansuyue@smu.edu.cn
Studieorter
-
-
Fujian
-
Fuzhou, Fujian, Kina
- Rekrytering
- Fujian Medical University Union Hospital
-
Kontakt:
- Shenggen Chen, M.D.
- Telefonnummer: 13459480275
-
-
Guangdong
-
Dongguan, Guangdong, Kina
- Rekrytering
- Dongguan People's Hospital
-
Kontakt:
- Zhu Shi, M.D.
- Telefonnummer: 13669825459
-
Dongguan, Guangdong, Kina
- Rekrytering
- Dongguan donghua hospital
-
Kontakt:
- Lingyu Sun
- Telefonnummer: 13829203368
-
Guangzhou, Guangdong, Kina
- Rekrytering
- Nanfang Hospital of Southern Medical University
-
Kontakt:
- Suyue Pan
- Telefonnummer: 13556184981
-
Guangzhou, Guangdong, Kina
- Rekrytering
- Guangdong Provincial Hospital of Traditional Chinese Medicine
-
Kontakt:
- Lixin Wang, M.D.
- Telefonnummer: 13922793886
-
Guangzhou, Guangdong, Kina
- Rekrytering
- Huadu District People's Hospital of Guangzhou
-
Kontakt:
- Guangning Li, M.D.
- Telefonnummer: 13926239656
-
Guangzhou, Guangdong, Kina
- Rekrytering
- The Fourth Affiliated Hospital of Guangzhou Medical University
-
Kontakt:
- Wangchi Luo, M.D.
- Telefonnummer: 13710895142
-
Heyuan, Guangdong, Kina
- Rekrytering
- Heyuan people's Hospital
-
Kontakt:
- Minzhen Zhu
- Telefonnummer: 15007622318
-
Huizhou, Guangdong, Kina
- Rekrytering
- Huizhou Municipal Central Hospital
-
Kontakt:
- Lizhi Wang, M.D.
- Telefonnummer: 13802872076
-
-
Hainan
-
Haikou, Hainan, Kina
- Rekrytering
- Hainan Provincial People's Hospital
-
Kontakt:
- Fan Zhang, M.D.
- Telefonnummer: 17389897580
-
Haikou, Hainan, Kina
- Rekrytering
- Haikou People's Hospital
-
Kontakt:
- Guoshuai Yang, M.D.
- Telefonnummer: 13876006248
-
Haikou, Hainan, Kina
- Rekrytering
- Hainan Traditional Chinese Medicine Hospital
-
Kontakt:
- Yong Gu, M.D.
- Telefonnummer: 15521280288
-
-
Hunan
-
Changsha, Hunan, Kina
- Rekrytering
- The First Hospital of Changsha
-
Kontakt:
- Xu Peng, M.D。
- Telefonnummer: 15802507292
-
Hengyang, Hunan, Kina
- Rekrytering
- The Second Hospital University of South China
-
Kontakt:
- Yanhong Hu, M.D.
- Telefonnummer: 13265004191
-
Yueyang, Hunan, Kina
- Rekrytering
- Yueyang People's Hospital
-
Kontakt:
- Yuan Zhou, M.D.
- Telefonnummer: 15107309796
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, Kina
- Rekrytering
- Sinopharm North Hospital
-
Kontakt:
- Lifei Xing, M.D
- Telefonnummer: 15354919958
-
Hohhot, Inner Mongolia, Kina
- Rekrytering
- The Affiliated Hospital of Inner Mongolia Medical University
-
Kontakt:
- Lihua Sun, M.D.
- Telefonnummer: 18686292585
-
-
Jiangxi
-
Ganzhou, Jiangxi, Kina
- Rekrytering
- Ganzhou City People's Hospital
-
Kontakt:
- Zhaohui Lai
- Telefonnummer: 13879729792
-
-
Zhejiang
-
Wenzhou, Zhejiang, Kina
- Rekrytering
- Second Affiliated Hospital of Wenzhou Medical University
-
Kontakt:
- Saijun Zhou, M.D.
- Telefonnummer: 13857746659
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients who are treated with mechanical thrombectomy with acute anterior circulation large vessel occlusion. ≥18 years of age, within 24 hours of onset. Expected survival >3 months. NIHSS score ≥ 6 at onset of illness.
Beskrivning
Inclusion Criteria:
- Age ≥18 years.
- Within 24 hours of onset. Meet the criteria for diagnosis of acute ischemic stroke in the "China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018".
- Meet the indications for mechanical thrombectomy in the "Chinese Guidelines for Early Endovascular Interventions in Acute Ischemic Stroke 2022".
- Treated with mechanical thrombectomy.
- NIHSS score ≥ 6 at onset of illness.
- Sign an informed notice.
Exclusion Criteria:
Allergy to drug ingredients. Women who are pregnant or breastfeeding. Life expectancy of less than 3 months due to other non-ischemic stroke diseases such as malignancy, severe liver or renal failure.
Have participated in other interventional clinical studies (affecting the outcome of this cohort study).
Participants who were judged by the investigator to be unsuitable for participation in this study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Stress Ulcer Prophylaxis
Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission. |
|
Control Group
Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
90-day mortality after onset
Tidsram: 90-day after onset
|
Proportion of enrolled patients who died 90 days after onset of disease. |
90-day after onset
|
|
Incidence of stroke-associated pneumonia
Tidsram: within 7-day of onset
|
Incidence of non-mechanically ventilated stroke patients with new pneumonia within 7-day of onset |
within 7-day of onset
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of clinically significant bleeding
Tidsram: within 7-day of onset
|
One of the following 4 symptoms occurs within 24 hours of bleeding from a stress ulcer (in the absence of other causes):1. A decrease of ≥ 20 mmHg in any one of systolic, diastolic and mean arterial pressure. 2.Initiation of blood pressure boosters or 20% increase in medication dose.3. Decreased hemoglobin ≥ 2 g/d((1.24 mmol/l). 4.Infusion of erythrocytes ≥ 2 U. |
within 7-day of onset
|
|
Incidence of stress ulcer bleeding
Tidsram: 7-day after onset
|
Coffee-like residue/black stool/blood in stool within 7-day after onset and more than 2 consecutive positive fecal/gastric fluid occult blood |
7-day after onset
|
|
Incidence of unfavorable functional prognosis at 90 days after onset
Tidsram: 90-day after onset
|
Incidence of unfavorable functional prognosis at 90 days after onset |
90-day after onset
|
|
90-day mRS score change
Tidsram: 90-day after onset
|
Modified Rankin Scale score change within 90 days after onset in patients who were eligible for inclusion criteria |
90-day after onset
|
|
Incidence of early neurological deterioration
Tidsram: within 72 hours after onset
|
Increased score of National Institutes of Health Stroke Scale within 72h after onset ≥ 4 |
within 72 hours after onset
|
|
1-year post-onset mortality
Tidsram: 1 year after onset
|
Mortality at 1 year after onset in patients who were eligible for inclusion criteria |
1 year after onset
|
|
Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset
Tidsram: 1 year after onset
|
Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset in patients who were eligible for inclusion criteria |
1 year after onset
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Suyue Pan, Department of Neurology, Nanfang Hospital,Southern Medical University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NFEC-2023-040
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .